Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-…

Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+8 more

Estimated

~$10 – $8,750

Radiopharm Theranostics, LtdNCT07189871

Phase 1

A Phase 1 Open-Label, Multicenter Study of JANX013 Combined With JANX007 in Participants With Metastatic Castration Resistant Prostate Cancer

This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the …

Prostate CancerCastration-Resistant Prostate Cancer (CRPC)Metastatic Prostate Cancer+1 more

Estimated

~$10 – $8,750

Janux TherapeuticsNCT07813637

Phase 2

MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an in…

Castration-Resistant Prostate Cancer (CRPC)Castration-Resistant Prostate CancerProstate Cancer+1 more

Estimated

~$10 – $8,750

Monte Rosa Therapeutics, IncNCT07745361

MAgnetic Resonance Imaging or Computed Tomography Guided Stereotactic Body Radiotherapy With Online Adaptive Technology for Minimizing Toxicity During Salvage or AdjUvaNt Radiotherapy for ProstatE Cancer (MASAMUNE)

Single-arm, prospective registry study assessing changes in acute patient-reported urinary (GU) and gastrointestinal (GI) quality of life at the 24-month post-…

Prostate Cancer (CRPC)

Estimated

~$10 – $750

Jonsson Comprehensive Cancer CenterNCT07077239

Phase 1

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic ER+, HER2- Breast Cancer

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study …

ER+, HER 2- Breast CancerNon-small Cell Lung Cancer (NSCLC)Castration-resistant Prostate Cancer (CRPC)+1 more

Estimated

~$10 – $8,750

IDEAYA BiosciencesNCT07540572

Phase 2

177Lu-PSMA-617 (Pluvicto) for the Treatment of Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Super Scan Bone Scan

The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prost…

Metastatic Castration-Resistant Prostate CancerProstate Cancer Patients With Bone MetastasisProstate Cancer (CRPC)+2 more

Estimated

~$10 – $7,500

Ebrahim S DelpassandNCT06972628

Phase 1

Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

TITLE: Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer (PHAROS) STUDY DES…

Metastatic Castration-resistant Prostate Cancer (CRPC)Metastatic Castration-resistant Prostate Carcinoma

Estimated

~$10 – $8,750

TechnoGenesys, Inc.NCT06705686